Brief: Resverlogix says announces successful phase 1 renal trial results
17/11/2016 13:00
Nov 17 (Reuters) - Resverlogix Corp RVX.TO
* Resverlogix - plans to initiate a phase 2 renal impairment
trial that is expected to commence in early 2017 based on pk
data confirmed in phase 1 trial
* Resverlogix announces successful phase 1 renal trial
results: clears path for future phase 2 studies
Source text for Eikon: ID:nCNW7vWMFa
Further company coverage: RVX.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment